129 related articles for article (PubMed ID: 20394794)
21. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.
Smith GC; Vickers MH; Shepherd PR
Arch Physiol Biochem; 2011 Oct; 117(4):241-9. PubMed ID: 21671852
[TBL] [Abstract][Full Text] [Related]
23. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
24. Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.
Sugai T; Suzuki Y; Fukui N; Ono S; Watanabe J; Tsuneyama N; Someya T
J Clin Psychopharmacol; 2012 Jun; 32(3):390-3. PubMed ID: 22544005
[TBL] [Abstract][Full Text] [Related]
25. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Perez-Iglesias R; Mata I; Pelayo-Teran JM; Amado JA; Garcia-Unzueta MT; Berja A; Martinez-Garcia O; Vazquez-Barquero JL; Crespo-Facorro B
Schizophr Res; 2009 Feb; 107(2-3):115-21. PubMed ID: 18993033
[TBL] [Abstract][Full Text] [Related]
26. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
27. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
Krakowski M; Czobor P; Citrome L
Schizophr Res; 2009 May; 110(1-3):95-102. PubMed ID: 19269139
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
[TBL] [Abstract][Full Text] [Related]
29. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.
Park S; Sang Mee Hong ; Il Sung Ahn ; Sung Hoon Kim
J Psychopharmacol; 2010 Jul; 24(7):1105-14. PubMed ID: 19965940
[TBL] [Abstract][Full Text] [Related]
31. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
32. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.
Graham KA; Perkins DO; Edwards LJ; Barrier RC; Lieberman JA; Harp JB
Am J Psychiatry; 2005 Jan; 162(1):118-23. PubMed ID: 15625209
[TBL] [Abstract][Full Text] [Related]
33. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.
Chrzanowski WK; Marcus RN; Torbeyns A; Nyilas M; McQuade RD
Psychopharmacology (Berl); 2006 Dec; 189(2):259-66. PubMed ID: 17058105
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Smith RC; Rachakonda S; Dwivedi S; Davis JM
Psychiatry Res; 2012 Oct; 199(3):159-63. PubMed ID: 22475524
[TBL] [Abstract][Full Text] [Related]
36. Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.
Daly EJ; Kent JM; Janssens L; Newcomer JW; Hüsken G; De Boer P; Tritsmans L; Schmidt ME
Ann Clin Psychiatry; 2013 Aug; 25(3):173-83. PubMed ID: 23926573
[TBL] [Abstract][Full Text] [Related]
37. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.
Ingole S; Belorkar NR; Waradkar P; Shrivastava M
Indian J Physiol Pharmacol; 2009; 53(1):47-54. PubMed ID: 19810576
[TBL] [Abstract][Full Text] [Related]
38. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.
Richards AA; Hickman IJ; Wang AY; Jones AL; Newell F; Mowry BJ; Whitehead JP; Prins JB; Macdonald GA
J Clin Psychopharmacol; 2006 Jun; 26(3):232-7. PubMed ID: 16702887
[TBL] [Abstract][Full Text] [Related]
40. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.
Baptista T; Dávila A; El Fakih Y; Uzcátegui E; Rangel NN; Olivares Y; Galeazzi T; Vargas D; Peña R; Marquina D; Villarroel V; Teneud L; Beaulieu S
Int Clin Psychopharmacol; 2007 Jul; 22(4):205-11. PubMed ID: 17519643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
